NCT02315352View on ClinicalTrials.gov

Cross-over Study to Evaluate the Palatability of New Orally Disintegrating Tablets (ODTs) of Praziquantel (PZQ) and L-PZQ Versus Current PZQ Tablets in African Children Age 6-11 Years

PHASE1CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

April 30, 2015

Primary Completion Date

May 31, 2015

Study Completion Date

May 31, 2015

Conditions
Healthy
Interventions
DRUG

L-PZQ ODT

L-PZQ ODT (MSC2499550A) tablet at a dose of 150 milligram (mg) put and disintegrated in the mouth without water

DRUG

Rac-PZQ ODT

Rac-PZQ ODT (MSC1028703A) tablet at a dose of 150 mg put and disintegrated in the mouth without water

DRUG

L-PZQ ODT

L-PZQ (MSC2499550A) tablet at a dose of 150 mg dispersed in water

DRUG

Rac-PZQ ODT

Rac-PZQ ODT (MSC1028703A) tablet at a dose of 150 mg dispersed in water

DRUG

Cesol®

Cesol® tablet at a dose of 150 mg crushed in water

Trial Locations (1)

Unknown

Ifakara Health Institute, Ikwiriri

All Listed Sponsors
collaborator

Swiss Tropical & Public Health Institute

OTHER

lead

Merck KGaA, Darmstadt, Germany

INDUSTRY

NCT02315352 - Cross-over Study to Evaluate the Palatability of New Orally Disintegrating Tablets (ODTs) of Praziquantel (PZQ) and L-PZQ Versus Current PZQ Tablets in African Children Age 6-11 Years | Biotech Hunter | Biotech Hunter